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Summary Pancreatitis-associated protein I (PAP I) is a secretory protein first described as an acute phase
reactant during acute pancreatitis. Recently, induction of the PAP I gene was also described in liver during
hepatocarcinogenesis. To investigate the molecular mechanisms of this induction, we used constructs carrying
progressive deletions of the PAP I promoter fused to the CAT gene. We showed that the silencer conferring
tissue specificity on the PAP I gene was inactive in hepatoma cells. Then, in an in vitro transcription system, we
compared the transcription capacity of nuclear extracts from normal liver and HepG2 cells on constructs
containing the silencer. The results confirmed that a trans-acting factor interacting with the PAP I silencer was
present in liver cells and absent from hepatoma cells. On the other hand, immunohistochemistry showed that
PAP I was expressed in a limited number of transformed hepatocytes. It was concluded that expression of PAP
I in hepatocarcinoma occurred through inactivation of its silencer element and was not concomitant in all
malignant cells. On that basis, we assayed PAP I in serum from patients with chronic hepatitis, liver cirrhosis
or hepatocarcinoma. PAP I levels were normal in chronic active or persistent hepatitis, significantly higher in
cirrhosis and strongly elevated in hepatocarcinoma. Because those clinical entities often develop in that
sequence, serum PAP I appeared as a potential marker of hepatocarcinoma development.
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Pancreatitis-associated protein (PAP) is a secretory protein
present in small amounts in normal pancreas and rapidly
overexpressed during the acute phase of pancreatitis (Keim et
al., 1991; Iovanna et al., 1991a). It was characterised as a
novel serum indicator of the course of acute pancreatitis
(lovanna et al., 1994). It was shown recently that PAP
belongs to a family of structurally related proteins whose
genes have similar organisation and the same chromosomal
location, suggesting that they are derived from a common
ancestor (Dusetti et al., 1993; Frigerio et al., 1993; Dusetti et
al., 1995a; Stephanova et al., 1996). In this family, we
described three PAPs, the original one becoming PAP I, and
two reg/lithostathines (Giorgi et al., 1989; Bartoli et al.,
1993). Their sequence contains a carbohydrate recognition
domain (CRD), typical of calcium-dependent lectins (Orelle
et al., 1992; Drickamer, 1988). They show among lectins the
peculiar features of being secretory proteins and having a
single CRD. In Drickamer's classification, they appear now
as the group VII or free CRD lectins (Drickamer, 1993).
Expression of PAP I is not restricted to the pancreas, upon
induction of pancreatitis. It is also constitutively expressed by
the epithelial cells of the small intestine (Dusetti et al., 1993;
lovanna et al., 1993; Masciotra et al., 1995; Kamimura et al.,
1992; Itho and Teraoka, 1993; Chakraborty et al., 1995) and
secreted by rat pituitary cells upon induction by growth-
hormone-releasing hormone (Tachibana et al., 1988; Katsu-
mata et al., 1995). In addition, Lasserre et al. (1992), using
differential screening of a human hepatocellular carcinoma
cDNA library, have cloned a mRNA, called HIP, which is
identical to PAP I. They found that PAP I was expressed at
high levels in 7 of 29 hepatocellular carcinomas but not in
normal or fetal liver.
Little is known about the pathophysiological significance
ofPAP I expression. It might be associated with regulation of
cell proliferation, as suggested in the pituitary (Tachibana et
al., 1988). This is supported by its constitutive expression in
the intestinal epithelium, where cellular turnover is very fast,
and by the triggering of the expression of the PAP-related
protein reg during islet cell regeneration (Terazano et al.,
1988). By contrast, PAP expression in the exocrine pancreas
could not be related to regeneration. It was typical of an
acute phase reactant, and topological analysis of the PAP I
gene showed the presence in the promoter of several cis-
acting elements responding to inflammatory mediators such
as cytokines (Dusetti et al., 1994a, 1995b).
The report of PAP I expression in liver during
carcinogenesis was the first evidence that the PAPs were
involved in cancer. This observation greatly extended the
potential importance of this family of proteins in human
pathology. As a result, the mechanism of PAP I induction
warranted analysis in hepatocarcinogenesis. We have demon-
strated that PAP I was synthesised in a fraction of the
transformed hepatocytes, and we localised within the
promoter of the PAP I gene a suppressor region whose
activity was inhibited in hepatoma cells. Also, because PAP I
is a secretory protein that may leak into blood, as it does
during acute pancreatitis (Iovanna et al., 1994), we decided to
determine whether serum PAP I concentrations would reflect
evolution of the disease, and we have showed that it
increased with hepatocarcinoma development.
Materials and methods
Molecular studies
Cell culture HepG2 hepatoma and Rat2 fibroblast cells were
purchased from the American Type Culture Collection.
HepG2 cells were routinely cultivated at 37°C in a 5%
carbon dioxide, 95% air atmosphere in Dulbecco's modified
Eagle medium containing 10% (v/v) fetal calf serum
(GIBCO), 4 mM L-glutamine, 50 U ml-' of penicillin and
50 Mg ml-' streptomycin. Rat2 cells were maintained in the
same culture conditions as HepG2 cells except that fetal calf
serum was 5%. When cells reached 80-90% confluence, they
were dissociated with 0.05% trypsin and 0.02% EDTA in
Puck's saline A and replated into 100 mm Petri dishes.
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Transfection assays
CAT reporter gene constructs All DNA constructs were
generated by polymerase chain reaction (PCR) using the
plasmid P/P as a template (Dusetti et al., 1993). That plasmid
is a pBluescript KS', in which was subcloned a 2859 bp PstI-
PstI genomic DNA fragment containing the PAP I gene
including 1253 nucleotides of the promoter. Accuracy of PCR
was increased by using low dNTP concentrations (Ehlen and
Dubeau, 1989), 100 ng of DNA plasmid as template and only
eight cycles of DNA amplification. Amplification was
performed in 1 x PCR buffer (50 mM potassium chloride,
10 mM Tris-HCl pH 8.3, 2 mm magnesium chloride and
0.01% gelatin) containing 2 Mm dNTP, 1% dimethyl sulph-
oxide (DMSO), 25 pmol of each primer and 2.5 units of Taq
polymerase in a final volume of 50 pl. The reaction times were
as follows: first cycle, denaturation at 94°C for 2 min, annealing
at 55°C for 2 min and extension at 74°C for 2 min; for the next
seven cycles, denaturation at 94°C for 10 s, annealing at 55°C
for 2 min and extension at 74°C for 2 min; for the last cycle,
denaturation at 94°C for 10 s, annealing at 55°C for 2 min and
extension at 74°C for 10 min. Seven fragments of the PAP I
promoter, of various lengths, were synthesised. The products
were kinased, blunt-ended with Klenow polymerase and ligated
into the SalI site of the promoterless vector pCAT-Basic
(Promega) to generate the plasmids p - 1253/ + lOPAPI-CAT,
p-926/+ lOPAPI-CAT, p-685/+ lOPAPI-CAT, p-444/
+ lOPAPI-CAT, p-180/ + lOPAPI-CAT, p-118/ + lOPAPI-
CAT, p-61/+ lOPAPI-CAT and p+ 10/-1253PAPI-CAT.
Figures in plasmid names refer to the positions offirst and last
nucleotides of the inserted fragments in the PAP I gene.
Activity ofthe - 180/-118 region on heterologous promoters
To test the influence ofthe - 180/ -118 region on heterologous
promoters, the appropriate 62 bp DNA fragment was PCR-
amplified and treated as described above to generate blunt
ends. The fragment was then subcloned into the SaIl site
(blunt-ended with Klenow polymerase) of ptkCAT vector
(Luckow and Schutz, 1987), which contains the CAT gene
driven by the herpes simplex virus thymidine kinase promoter.
DNA purification Plasmid DNA was purified with the
Quiagen plasmid kit (Diagen, Hilden, Germany), and the
DNA concentration was measured by spectrophotometry.
Sequences were verified by the chain termination method,
using the T7 Sequencing Kit (Pharmacia). Plasmids were also
checked for purity, concentration, supercoiling and restriction
pattern using agarose gel electrophoresis.
Cell transfection and CAT assays Fifty to sixty per cent
confluent HepG2 and Rat2 cells in 100 mm Petri dishes were
transfected using the calcium phosphate DNA co-precipita-
tion method (Graham and van der Eb, 1973). Culture
medium was changed 3 h before transfection. The transfec-
tion mixture contained 15 Mg of test plasmid and 5 Mg of
pCMV/,B-gal plasmid (Promega). Four hours after the
addition of the DNA, cells were treated with 20% (v/v)
glycerol for 2 min, washed with serum-free medium and
transferred to serum-containing medium. Each construct was
transfected in triplicate. In all cases, at least two separate
plasmid preparations were tested in the transfection
experiments. At 48-72 h after transfection, cell extracts
were prepared using the reporter lysis buffer (Promega).
CAT activity was determined using a phase extraction
procedure (Seed and Sheen, 1988), and P-galactosidase
assays were performed essentially as previously described
(Sambrook et al., 1989). CAT and fl-galactosidase activities
were always within the linear range of the assay.
In vitro transcription assays
Plasmid construction Plasmids p(C2AT)19 and
pML(C2AT)19 were received from M Sawadogo (Sawadogo
and Roeder, 1985). The - 180/+10 and -118/+10 regions
of the PAP I promoter were PCR-amplified as described
above, except that primers at positions - 180 and -118 were
designed to contain an EcoRI restriction site. These
fragments were fused to the G-less cassette into blunt-ended
Sacl and EcoRI sites. Correct orientation and absence of
mutation was controlled by direct sequencing as described
above.
Nuclear extract preparations Liver nuclear extracts from 3-
month-old Sprague -Dawley rats were prepared according to
Gorski et al. (1986). Nuclear extracts from Rat2 and HepG2
cells were prepared essentially by the method of Roy et al.
(1991) with minor modifications. Briefly, approximately
5x108- 109 cells were scraped, collected and washed once
with cold phosphate-buffered saline. Cells were then
resuspended in the NEI buffer (250 mM sucrose, 20 mM
HEPES pH 7.9, 140 mM sodium chloride, 2 mM EDTA,
5 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine, 1 mM,
dithiothreitol, 25 mM potassium chloride, 2 mM magnesium
chloride and 0.4 mM phenylmethylsulphonyfluoride) with
0.5% Nonidet P-40 and homogenised using a Dounce
manual-type tissue grinder (10 strokes). Nuclei and cell
debris were centrifuged for 7 min to 400 g at 4°C. The
supernatant was discarded, and nuclei were then lysed by
incubation at 4°C in 2 ml of NE2 buffer (NEI buffer
containing 350 mM potassium chloride) followed by homo-
genisation using the Dounce tissue grinder (20 strokes). The
homogenate was ultracentrifuged at 180 000 g for 90 min.
The supernatant was dialysed against 250 ml of a buffer
containing 75 mM potassium chloride, 0.25 mM EDTA,
20 mM HEPES pH 7.9, 1 mm dithiothreitol, 10% glycerol,
1 mM phenylmethylsulphonylfluoride, 1 Mg ml-' leupeptin,
1 Mg ml-' pepstatin, 10 Mg ml-' aprotinin and 40 Mg ml-'
bestatin and kept frozen at -80°C in 100 Ml aliquots. Protein
concentration was determined by the method of Bradford
(1976).
In vitro reactions The transcription reactions (20 Ml) were
performed as described by Gorski et al. (1986) in a buffer
containing 25 mM Hepes (pH 7.6), 50 mmpotassium chloride,
6 mM magnesium chloride, 0.6 mM each of ATP and CTP,
35 pM UTP, 7 ,Ci [a-32P]UTP, 0.1 mM 3'-O-methyl GTP, 12%
glycerol and 1 Ml of RNAsin. After 45 min of incubation at
30°C, the reactions were terminatedby the addition of380 ,lof
stop buffer (50 mM Tris-HCl pH 7.5, 1% sodium dodecyl
sulphate (SDS), 5 mM EDTA, 25 Mg ml-' of yeast tRNA).
Optimal transcription efficiency was obtained using 30 Mg of
nuclear extracts and 400 ng of template. The RNA was
precipitated by addition of 40 pl of 3 M sodium acetate
(pH 4.8) and 880 Ml of ethanol. The RNA pellets were
resuspended in 10 Ml of loading mix (80% formamide, 0.01%
xylene cyanol and 0.01% bromophenol blue in 1 xTBE), and
an aliquot of 4 pl was then loaded on a 6% polyacrylamide-
7 M urea sequencing gel. Autoradiography was carried out at
-80°C with intensifying screens for 3 days. Autoradiograms
were quantitated by densitometry.
Footprinting assays The synthetic DNA fragment -378 to
+ 10 of the PAP I gene was used in footprint analysis. Either
the 5' or the 3' specific primers were labelled with [y-32P]ATP
and T4 polynucleotide kinase before PCR amplification.
Footprint analysis was performed in a 20 Ml reaction
containing 25 mM Hepes pH 7.5, 40 mM potassium chlor-
ide, 25 mM magnesium chloride, 25 pM zinc chloride, 25 mM
calcium chloride, 10% glycerol, 1 mM dithiothreitol, 0.02%
Nonidet P-40, 1 Mg of double-stranded poly(dI-dC), 50 ng of
sonicated salmon sperm DNA, 12-36 Mg of nuclear extracts
and 1.5 x 104 c.p.m. of end-labelled fragment. Following an
incubation of 20 min at 20°C, different amounts of DNAase I
(freshly diluted) were added, and the reaction was allowed to
proceed for 1 min at 20°C. The reaction was stopped by the
addition of 140 Ml of 768 mm sodium acetate, 128 mM
EDTA, 0.56% SDS and 256 Mg ml-' of yeast tRNA. TheDNA was extracted once with phenol/chloroform, precipi-
tated with two volumes of ethanol, resuspended in 98%
formamide dye and electrophoresed on a 8% polyacryla-
mide-7.5 M urea sequencing gel.
Immunocytochemistry
Immunocytolocalisation was performed on thin sections
(5 pm) of hepatocellular carcinoma or normal liver (as
control) using the peroxidase-antiperoxidase method of
Stenberger et al. (1970). Sections were exposed to the
primary antiserum (Keim et al., 1992), diluted 1:800, for
1 h. To test the specificity of the immunocytochemical
reaction, the following controls were used: (1) normal rabbit
serum was substituted to the specific antiserum, and (2) the
specific antiserum was preabsorbed with pure pancreatic PAP
(Keim et al., 1992) (100 pg ml-' of undiluted antiserum) at
4°C for 16 h with constant agitation.
Clinical study
Patients A total of 207 patients divided in five groups were
included. Group I included 40 patients (22 men; 18 women)
of mean age 43.5 + 13 years, suffering from chronic
persistent hepatitis (CPH). Group II consisted of 41
patients (23 men, 18 women) of mean age 46.1+11.7 years
suffering from chronic active hepatitis (CAH). Group III
was composed of 25 patients (17 men, 8 women) of mean
age 52.9+8.3 years, suffering from liver cirrhosis (LC). In
all these patients, diagnosis was made on the basis of
histological findings, and in all cases the disease was
associated with the presence in the serum of antibodies
against hepatitis C virus (HCV). Group IV included 34
patients (20 men, 14 women), of mean age 66.4+9.7 years,
with hepatocarcinoma-associated liver cirrhosis. The disease
was associated in six cases with the presence of hepatitis B
virus (HBV) markers, in 25 cases with anti-hepatitis C virus,
and in 4 cases it could not be associated with any known
cause of liver disease. In these patients, diagnosis was based
on histological findings. Finally, Group V was composed of
67 healthy asymptomatic subjects (37 men, 30 women) of
mean age 44.1 +7.2 years, who were recruited from blood
donors. They were free of hepatic disease on the basis of
careful anamnestic, biochemical and instrumental data. In
none of the five groups was daily consumption of alcohol
greater than 50 g ethanol day-', as evaluated by direct
interview with the patient and close relatives. A blood
samples was taken from all subjects in the morning after
fasting for at least 12 h. Common parameters of liver
function were evaluated in sera. An aliquot of serum from
each patient was stored at -40°C for the PAP assay, which
was performed within 30 days. This protocol received
approval from the Ethics Committee of the Palermo
University Hospital.
Biochemical tests Serological testing for anti-HCV was
performed using a commerical second generation enzyme-
linked immunosorbent assay (ELISA, Ortho Diagnostic
System, Raritan, NJ, USA), in accordance with the
manufacturer's instructions. Anti-HCV reactive samples
were confirmed using second generation anti-HCV recombi-
nant immunoblot assay (RIBA II, Chiron Corporation,
Emeryville, CA, USA). Markers of HBV were tested using
Abbot Ria Kit. Alphafetoprotein (AFP) was dosed using an
immunoluminometric method (Byk Sangtec, Milan, Italy).
According to the manufacturer's instructions, normal range
values were 0-200 IU 1-1. The main biochemical parameters
of liver function were assayed using commerically available
kits.
Liver biopsy Liver biopsy specimens were obtained percu-
taneously with a Menghini needle. Chronic liver diseases were
classified according to the De Groote criteria (De Groote et
al., 1968).
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Serum PAP level determination Serum PAP levels were
assayed by a sandwich ELISA following the manufacturer's
instructions (Dynabio, La Gaude, France). Briefly, coating
was performed by placing in each well 100 pl of anti-PAP
polyclonal antibody at a concentration of 5 pg ml-' in
phosphate buffer which was incubated overnight at room
temperature. Saturation was performed by adding in each
well 200 pl of 2% bovine serum albumin (BSA) in phosphate
buffer. Plates were incubated 90 min at room temperature.
Wells were then washed with 0.1% Tween in phosphate
buffered saline (PBS). Eighty microlitres of diluted (1:100)
serum were then placed in each well, incubated for 3 h at
room temperature and washed several times. Eighty ,ul per
well of biotinylated anti-PAP IgGs at 3 pg ml-' in PBS
containing 10% rabbit serum were then added as a second
antibody for 30 min. After washing, 80 pl of avidin-
peroxidase 1:5000 in PBS was added to each well for
15min and, after washing, 80,ul of OPD were substituted
and incubated 15 min in the dark. Finally, the reaction was
stopped with 80 Ml of sulphuric acid, 2 N, and samples were
read at 492 nm. Quantification was made by comparison with
a calibration curve obtained with serial dilutions of
recombinant PAP.
Statistical analysis Data were expressed as mean+s.d.
Distribution was described by the 'box and whiskers'
representation, the boxes enclosing 50% of the data around
the median and the whiskers extending to the points being
within 1.5 times the interquartile range. The Kruskal-Wallis
test was used to compare PAP concentrations between study
groups. Pearson's r correlation was used to evaluate the
correlation between individual values of PAP and values of
the different tests of hepatic function.
Results
PAP I gene transcription in the hepatoma HEPG2 cell line
The PAP I gene is efficiently transcribed in hepatoma HepG2
but not in fibroblast Rat2 cells A prerequisite to these
experiments was that endogenous PAP I mRNA is expressed
in HepG2 cells. This was demonstrated using a reverse
transcriptase-polymerase chain reaction (RT-PCR) ap-
proach with specific human PAP I primers, as already
reported (Dusetti et al., 1994b) (not shown). To identify the
DNA domains involved in the tissue-specific regulation of the
PAP I gene expression, we dissected the 5' flanking region of
this gene by progressively deleting the upstream sequence in
the 5' to 3' direction. The ability of these segments to drive
the expression of the bacterial chloramphenicol acetyltrans-
ferase (CA2) gene was tested in short-term expression
experiments. Plasmids carrying the progressively deleted
PAP I regulatory regions (Figure 1) fused to the CAT gene
were transfected, in parallel, into both the hepatoma HepG2
cell line and the fibroblast Rat2 cell line. The relative level of
expression of these different plasmids was determined by
enzymatic CAT assay. Progressive deletions in the 5' to 3'
direction resulted in a stepwise decrease of CAT gene
expression in the HepG2 cell line (Figure 1). Deletions
down to the -685 position caused a 25% decrease of
expression. Deletion of the sequences from -685 to -444
did not significantly affect the expression, however deletion of
the sequences from -444 to - 180 caused a 4-5 fold
decrease of expression. Deletion of the sequences to position
- 118 did not have any additional effect, but a further
deletion of 53 bp (to position -65) resulted in a significant
reduction (about 10-fold) of the activity. In Rat2 cells, a cell
line that does not express PAP I mRNA (Dusetti et al.,
1995c), deletions from -1253 to -180 did not affect CAT
expression. However, deletion from -180 to -118
significantly increased the expression (about 5-fold). Dele-
tions down to- 118 decreased the CAT activity by about 5-
fold. Similar results were obtained with other cell lines that
do not express PAP I (data not shown). These data suggestExpression of PAP in hepatocarcinoma
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the presence of a negative cis-acting sequence element
between -180 and -118 in the PAP I gene that confers
tissue-specific expression. This negative element was inactive
in the hepatoma cells.
Cell-specific activity ofthe -1801-118 region on heterologous
promoter Many cis-acting elements can regulate expression
of heteropromoters (Rosenthal, 1987). To check the cell
specific activity of the - 180/- 118 region of the PAP I
promoter, this fragment was inserted upstream from the
thymidine kinase promoter (Figure 2, plasmid p- 180/
-118PAPI/TK-CAT) driving the reporter CAT gene. It is
important to note that this region of the PAP promoter is
strongly conserved between rat and human genes as
previously reported by Dusetti et al. (1994b) and others
(Lasserre et al., 1994). These constructs were transfected in
Rat2 and HepG2 cells, and CAT activity was measured. The
results are illustrated in Figure 2. The PAP I promoter
fragment worked as a powerful negative cis-acting element in
Rat2 cells when it was inserted upstream of the thymidine
kinase promoter, in both orientations. However, this
fragment was, as expected, inactive in HepG2 cells. These
results confirm that the negative activity of the -180/-118
region is promoter and orientation independent, but cell
specific.
Absence of the PAP I silencer activity in the hepatoma
cells The PAP I mRNA is strongly expressed in hepatoma
cells, but not in normal hepatocytes. We speculated that the
silencer element described above, localised within the - 180/
-118 region of the PAP I promoter, was derepressed in
hepatoma cells. This hypothesis was investigated by analysing
the specificity of transcription of the PAP I promoter in vitro
using nuclear extracts obtained from Rat2 cells, rat liver (in
which the promoter is inactive) and hepatoma HepG2 cells
(in which the promoter is active). All constructs used as in
vitro templates contained the G-less reporter cassette
(Sawadogo and Roeder, 1985). Using the vector p(C2AT)19,
we constructed two plasmids containing regions - 180/ +10
and -118/+10 upstream of the G-free cassette. These
templates are referred to as p- 180/ + IOPAPI(C2AT)19 and
p- 118/ + lOPAPI(C2AT)19 respectively. As a positive control
for the transcriptional competence of our extracts, we used
the same G-free cassette under the direction of the
Adenovirus-2 major late (AdML) promoter (referred to as
pML(C2AT)19), which is a very strong promoter in most in
vitro systems. The vector (pC2AT)19 was used as negative
control. Results are described in Figure 3. pML(C2AT)19 was
CATconstructs
-10
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-926
-685
-444
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Relative CAT
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HepG2 Rat2
115± 21
98 ±12
83± 11
13 ±3
11 ±4
12 ±4
78±9 15±3
21 ±4 16 ±2
21±3 88±11
3 1 15±4
100± 11 100 ± 12
1±1 3± 1
Figure 1 Deletion analysis of the PAP I promoter. Relative
CAT activity±s.e.m. in extracts from HepG2 and Rat2 cells
transfected with the corresponding plasmids. CAT activity was
normalised for transfection efficiency, using the ratio of CAT
activity to ,B-galactosidase activity and was expressed as a
percentage of the pTK-CAT activity. Results are mean values
for at least six experiments for each cell type.
CATconstructs Relative CATactivity
HepG2 Rat2
pTK-CAT 100± 11 100±21
p-180/-1 18PAPl/ K-CAT-_-3 106 ± 13 43 ± 6
p-118/-1P80PAPI/TK-CATT 121 ±115 35±4
Figure 2 Identification of a silencer element in the PAP I
promoter which is active in front of a heterologous promoter in
Rat2 but not in HepG2 cells. Relative CAT activities+s.e.m. in
extracts from HepG2 and Rat2 cells transfected with the
corresponding plasmids. CAT activity was normalised for
transfection efficiency as described in Figure 1. The amount of
CAT activity detected when pTK-CAT was transfected was
arbitrarily set at 100 for each cell line. Results are mean values for
at least six experiments for each cell type.
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Figure 3 In vitro transcription of p-118/+lOPAPI(C2AT)19
and p-180/+IOPAPI(C2AT)19 in HepG2 cells, rat liver and
Rat2 cells nuclear extracts. Equal amounts of each plasmid
(400ng) were incubated with 30 ig of nuclear extracts from
HepG2 cells, rat liver or Rat2 cells as described in Materials and
methods selection. The in vitro transcription products were
analysed on a 6% polyacrylamide-7M urea sequencing gel. The
in vitro transcription products from pML(C2AT)19 and
p(C2AT)19 were used as positive and negative controls
respectively. Specific transcription products are indicated by
arrows. The amount of radioactivity incorporated into each
transcript was quantitated by densitometry of the autoradio-
grams.
HepG2
Liverefficiently transcribed in Rat2 cells, rat liver and HepG2 cell
nuclear extracts. p - 118/ +lOPAPI(C2AT)19 was also tran-
scribed with the three nuclear extracts. However, specific
transcription from the p-180/ + IOPAPI(C2AT)19 was
strongly repressed (about 11- and 4-fold) with nuclear
extracts from Rat2 cells and rat liver respectively. In
contrast, transcription of p-180/+lOPAPI(C2AT)19 re-
mained unaffected with extracts from hepatoma cells. These
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Figure 4 DNAase I Footprinting assays of the proximal PAP I
promoter region. The DNA fragment (-378 to + 10) was
labelled with [y-32P]ATP and T4 polynucleotide kinase. Increas-
ing amounts of nuclear extracts from HepG2 cells, rat liver and
Rat2 cells were used (12, 24 or 36pg reaction, represented by the
top triangle). Control reactions (0) were incubated with 24 jg of
BSA. Binding reactions and DNAase I treatment were carried out
as described in Materials and methods section. G+A represents
the sequences ladder. The relative positions of the DNAase I
protected regions are indicated by boxes on the right of each
autoradiogram.
Table I Correlations between serum values of PAP and some
parameters of liver function in patients with hepatocellular
carcinomas
r P
Albumin -0.54 <0.0001
Total bilirubin 0.14 NS
y-Globulin 0.28 <0.03
Platelets -0.25 <0.004
Prothrombin -0.24 <0.01
AFP 0.12 NS
ALT -0.05 NS
AFP, alphafetoprotein; ALT, alanine aminotransferase.
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results suggest that rat liver and Rat2 cells contain a trans-
acting factor, interacting with the - 180/- 118 promoter
region and repressing the transcription of the PAP I gene.
This factor seems to be absent from hepatoma cells.
Footprint analysis of the proximal promoter region of
PAP I As p- 180/+ lOPAPI-CAT contains the cell-
specific elements, we chose to probe the region between
nucleotides -378 and + 10 for specific DNA-protein
interaction with nuclear protein extracts prepared from
Rat2 cells, normal liver and HepG2 cells. Figure 4 shows
that several DNA segments were protected by proteins
present in these nuclear extracts. The location of the
protected regions, relative to the transcription start site, are
indicated in Figure 4.
Immunohistochemical localisation of PAP I in HCC
A monospecific polyclonal antibody was used to determine
by immunohistochemistry which cells produced PAP I in
hepatocellular carcinoma (HCC). Three primary hepatocel-
lular carcinomas were analysed. Non-neoplastic liver tissues
from the same patients were available in all three cases. The
PAP I was detected in all three carcinoma samples but in
none of the control liver specimen. The strong cytoplasmic
staining involved only a small number of transformed
hepatocytes (Figure 5a and b). In addition, transferred cells
forming bile duct-like structures could also be occasionally
stained (Figure 5c), whereas other cell types, such as
endothelial cells, were negative. Appropriate controls
established the specificity of the reaction.
PAP serum levels
Figure 6 shows the distribution of PAP values in the five
study groups. Values in patients with chronic active or
persistent hepatitis were not different from those of controls
(median values at 38 and 39, compared with 34 ,ug 1-'). A
significant increase, compared with controls, was observed in
patients with liver cirrhosis (P<0.01, median value at
43 ,ug 1') with 4 out of 25 patients showing values over
the upper threshold of normal values (90jug 1-. The increase
was much more significant in patients with hepatocarcinoma
compared with controls and also cirrhotic patients
(P<0.0001). In the HCC group, 64% of patients had PAP
values above the normal threshold. Table I shows correla-
tions between PAP levels and a series of parameters of liver
function. There was a negative correlation between PAP and
albumin of prothrombin levels, two indicators of protein
synthesis in liver (P<0.0001 and P<0.01 respectively) or the
number ofcirculating platelets (P<0.004). There was a direct
correlation with y-globulin levels (P<0.03). In contrast, there
was no significant correlation between PAP I serum
concentrations and the parameters of cytolysis or serum
levels of AFP (Table I and Figure 7).
Discussion
In the decade that followed the original characterisation of
PAP I in rat pancreatic juice, the PAP family has extended to
more than a dozen proteins whose expression occurs in many
tissues and shows in these tissues different patterns of
regulation. Such ubiquity, suggesting an important physiolo-
gical function, aroused further interest when PAP I
expression was found associated with pathological situa-
tions. Important induction was reported in pancreas during
development of acute pancreatitis (lovanna et al., 1991a, b),
and, more recently, PAP I was described in liver during
hepatocarcinogenesis (Lasserre et al., 1992). The molecular
mechanism of PAP I induction during the acute phase of
pancreatitis has been extensively analysed (Dusetti et al.,
1994a, b). The promoter allows expression in normal
pancreas, the tissue specificity being controlled by a silencer
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Figure 5 Immunolocalisation of PAP I in hepatocellular carcinoma tissues. The protein was immunodetected in thin sections of
hepatocellular carcinoma from cases a, b and c with a polyclonal antibody to the PAP I and a peroxidase-antiperoxidase secondary
antibody. Original magnifications: a and b, x 700; c, x 280. Normal liver was used as control in d ( x 200). PAP serum values before
surgical intervention were 338, 297 and 1110pg -1 for cases a, b and c respectively.
element turned off in pancreas by trans-acting cellular factors
(Dusetti et al., 1995c). Activity remains very low in normal
tissue and induction is triggered by factors released during
inflammation, such as cytokines, which is typical of acute-
phase reactants. Members of the PAP family are apparently
the only pancreatic proteins that are always induced during
pancreatitis (Frigerio et al., 1993; Dusetti et al., 1995a;
lovanna et al., 1991a; Rouquier et al., 1991).
The available information on PAP I expression during
liver carcinogenesis suggested a more complex situation.
Other proteins, such as the AFP, were also induced.
However, those proteins appeared to be expressed in
consequence of the dedifferentiation of the hepatocytes
because they were also found in the regenerating liver and
during liver development (Tsutsumi et al., 1994). By
contrast, PAP I was not observed in fetal or regenerating
liver (Lasserre et al., 1992), suggesting a mechanism
specifically related to carcinogenesis. Activation of the
PAP I gene expression during carcinogenesis does not seem
to be liver specific, because most of the studied
cholangiocarcinoma and stomach cancers also expressed
high levels of PAP I mRNA. However, PAP I mRNA
expression is not a constant factor during carcinogenes. For
example, we have found no induction in any of 12 colorectal
carcinoma (unpublished results).
Because control of tissue-specific expression by a silencer
is an elaborate mechanism, we made the hypothesis that it
had been lost during hepatic carcinogenesis. This was tested
in hepatoma cells transfected with progressive deletions of
the PAP I promoter fused to the reporter gene CAT. The
silencer, corresponding to the region between nt -118 and
- 180 of the promoter, prevented CAT expression in
fibroblast (Rat2) cells, as expected, and was indeed inactive
in hepatoma (HepG2) cells in which abundant CAT
expression was observed (Figures 1 and 2). This experiment
would have been optimally controlled if, in normal
hepatocytes, no CAT expression was obtained with the
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Figure 6 Serum PAP I concentrations. Serum PAP I concentra-
tion was measured in patients suffering from chronic persistent
hepatitis (CPH) (n=40), chronic active hepatitis (CAH) (n=41),
liver cirrhosis (Ci) (n =25), hepatocarcinoma (HCC) (n =34) or in
healthy asymptomatic subjects (Co) (n =67). For each group,
boxes enclose 50% of the values around the median (dotted line).
Vertical lines extend to data within 1.5-fold the interquartile
range. Values outside that range appear as dots. Values from Ci
patients were significantly different from values from Co, CAH
and CPH (P<0.01) and HCC (P<0.0001). Values from HCC
patients were significantly different from all groups (P<0.0001).
same construct. Because normal hepatic cell lines are not
available, we had to control our findings by using the in
vitro transcription system developed by Sawadogo and
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these putative trans-acting factors was c
I footprinting assay with nuclear extra
normal rat liver and HepG2 cells. I
Figure 4 revealed that similar regions
protected with the three extracts, b
protection were different. It was con
nuclear proteins bind to that region of 1
suggesting that the mechanism controllii
the PAP I gene for induction was con
the patterns observed with normal
hepatocytes probably account for the
PAP I gene during hepatocarcinogent
detailed analysis of the factor(s) involve(
understand the mechanism. Differen
pattern are not very significant betwee
or not expressing PAP I mRNA, perhal
acting factor responsible for silencing
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expression of the trans-acting factor:
specificity is altered during carcinogenes
Inactivation of the tumour-suppressoi
1985; Murphree and Benedict, 1984; H
1987; Ueba et al., 1994; El-Deiry et al
AFP, de-activation of a repressor (
differentiated cells were suggested as I
(Vacher and Tilghman, 1990).
Inactivation of the silencer is not suffic
expression in hepatoma, but should all
elements of the promoter to become fu
Figure 1 suggest the presence of at
regulatory domains, located between n
between nt -444 and -181 and between
addition, we demonstrated that induci
promoter was indeed possible in hepaton
ing HepG2 cells with the PAP I promoter
obtaining a 25-fold increase in CATexpre:
with interleukin 6 (IL-6) (not shown
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including other PAP I promoter-CAT constructs and
footprinting assays, will be necessary to characterise the active
regions and their trans-acting factors.
Like AFP and the CEA (Brumm et al., 1989; Ma et al.,
1993), PAP I was found expressed in a subset of
hepatocarcinoma cells only. Immunochemical analysis of
three tumour specimens (Figure 5) localised the protein to
transformed hepatocytes and to some oval cells whose
origin, presumably ductal, remains controversial (Dunsford
et al., 1989). Restricted expression of those markers to
certain transformed cells is probably explained by the fact
that transformation does not occur simultaneously in all
cells and may even proceed at different rates in different
cells. Also, their expression may correspond to a certain
stage of transformation and therefore be transient if further
transformation results in the loss of appropriate positive
300 1I00 1200 trans-acting factors. The observation that serum PAP I
Dn00g 10
0 levels were elevated in a majority of patients with
Dnl (,u9 F) hepatocarcinoma (Figure 6) suggested that sustained overall
kP I serum concentra- PAP I expresion occurred in advanced stages of cancer
noma. No significant development. Table I shows negative correlations with
m concentrations was circulating levels of albumin, prothrombin or platelet
rcinoma (n= 34). number and direct correlation with levels of y-globulin.
These correlations could be explained by the fact that all the
patients included in this study have developed their HCCs
on cirrhotic livers. It is known that cirrhosis is accompanied
scription capacity of by decreased albumin, prothrombin and platelet number and
er, Rat2 cells and increased y-globulin level. However, common mechanisms
ig the -180/-118 regulating the PAP I mRNA induction and induction of y-
swn in Figure 3, the globulin remain to be explored. There was however no
icts was absent when correlation between PAP I and AFP serum concentrations in
also from normal these patients (Figure 7), indicating that the two proteins
Ld probably lost the were not concomitantly expressed.
in nuclear extracts Lasserre et al. (1992) have described expression of PAP I
y characterisation of mRNA in about 25% of the HCCs, whereas in our study
)btained by DNAase the serum PAP levels were increased in more than 60% of
Lcts from Rat2 cells, the patients. These discrepancies could be explained by the
tesults presented in fact that the PAP ELISA system is more sensitive than
of the silencer were Northern blot. In addition, PAP serum assays reflect global
ut the patterns of synthesis of the protein by all hepatocarcinoma cells,
icluded that several whereas Northern blot analysis would reflect PAP I mRNA
the PAP I promoter, expression in the tissue sample selected for RNA extraction
ng the availability of and analysis. However, the number of patients included in
nplex. Differences in the two studies is not large enough to completely exclude
and transformed sampling heterogeneity.
derepression of the PAP I expression in hepatocarcinoma raised the question
esis, although more of its usefulness as a marker of the disease. As a first step
d is required to fully towards addressing this question, we assayed PAP I in serum
ces in footprinting from patients with chronic hepatitis, liver cirrhosis and
-n tissues expressing hepatocarcinoma because those three clinical entities often
ps because the trans- develop in that sequence. PAP I serum concentrations were in
is present at low the normal range (under 90 ug 1-') in most patients with
ble that this nuclear persistent or active chronic hepatitis. In patients with
r our experimental cirrhosis, its average value was significantly higher than in
hanisms by which controls and was above the threshold of normal values in
s controlling tissue 16% of the patients. The increase was more marked in
sis remain unknown. hepatocarcinoma, with two thirds of the patients showing
r factor (Knudson, values above 90 jug 1-', some of them being extremely high.
lansen and Cavenee, Results from this retrospective study suggest that serum PAP
I., 1993) and, as for I should be further evaluated as a marker of hepatocarcino-
element specific to ma. It would be particularly interesting to monitor the
possible mechanisms clinical evolution of cirrhotic patients with elevated serum
PAP I. In addition, because AFP and PAP I inductions occur
,ient to induce PAP I by independent mechanisms during hepatocarcinogenesis,
Low other regulatory their use as a combination of serum markers might improve
nctional. Data from hepatocarcinoma diagnosis. Previous studies have shown that
least three positive AFP was elevated in 50-70% of patients (Sato et al., 1993).
t -926 and -685, In our sample, that proportion was 58%. However, those
nt - 118 and -65. In patients in which both AFP and PAP I were elevated
tion of the PAP I amounted to 79%.
na cells by transfect-
-CATconstruct and
ssion upon treatment
). Further analysis,
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